Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 63

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 63
---
 retainer for Lead Independent Director:                                          |     |   |       25,000 |     |   |        25,000 |
| Additional retainer for Chair of Audit Committee:                                           |     |   |       20,000 |     |   |        20,000 |
| Additional retainer for Chair of Compensation Committee:                                    |     |   |       15,000 |     |   |        15,000 |
| Additional retainer for Chair of Science Committee:                                         |     |   |       15,000 |     |   |        15,000 |
| Additional retainer for Chair of Nominating and Corporate Governance Committee:             |     |   |       10,000 |     |   |        15,000 |
| Additional retainer for non-Chair members of Audit Committee:                               |     |   |       10,000 |     |   |        10,000 |
| Additional retainer for non-Chair members of Compensation Committee:                        |     |   |        7,500 |     |   |         7,500 |
| Additional retainer for non-Chair members of Science Committee:                             |     |   |        7,500 |     |   |         7,500 |
| Additional retainer for non-Chair members of Nominating and Corporate Governance Committee: |     |   |        5,000 |     |   |         7,500 |

#### Equity Compensation
Under our Compensation Program for Non-Employee Directors, we automatically grant an initial equity award having a grant date fair value of approximately $750,000 on the date the person becomes a director of the company. Further, we automatically grant an annual equity award having a grant date fair value of approximately $400,000 on the date of our annual meeting of stockholders. Initial and annual equity awards will be split between stock options and RSUs, with approximately 2/3 of the value delivered through stock options and the remaining 1/3 through RSUs.

Options granted as part of an initial or annual equity award will have an exercise price equal to the Fair Market Value (as defined in our 2018 Equity Incentive Plan) on the date of grant. Subject to the director’s continuous service on the Board, initial option awards shall vest and become exercisable in substantially equal monthly installments over 36 months and initial RSU awards shall vest in three substantially equal annual installments. Subject to the